Nunaps has raised $4.3 million in Series A round for developing patient-centric digital therapeutics platform for brain damage.
FREMONT, CA: A South Korean digital therapeutics startup, Nunaps has managed to secure $4.2 million in Series A round led by K2 Investment Partners, Company K Partners, and KTB Network. Nunaps plans to use the raised capital for building digital therapeutics platform related to neurological disorders. The company has also recently initiated an essential clinical trial of its first product, Nunap Vision. This new product offers visual perceptual training to treat visual field defects caused by brain damage. Nunap Vision is Software as a Medical Device (SaMD) utilizing HMD VR and is the first digital therapeutics trial approved by MFDS in South Korea.
Nunap Vision's clinical efficacy has already been demonstrated in previous proof-of-concept studies and has designed the pivotal clinical trial to be double-blind, multi-center, randomized, and placebo-controlled for further validation. Nunaps considers its in-house convergence medical and tech experts comprised of software and game/VR developers, engineers, perceptual psychologists, AI scientists, neurologists, and mathematicians as an asset. The company plans to develop pipelines for various brain disorders to become a pioneering digital therapeutics platform company in the coming years. Nunaps is the pioneering digital therapeutics organization in Korea and has the potential to become a global top-tier, establishing up clinical trials for new digital therapeutics that employ AI to address neurological disorders.
Nunaps is a Korean-based digital therapeutics startup, enabling digital therapies to enhance vision impairment after brain surgery. The company's proprietary product Nunap Vision is software for VR devices that combines the theory of blindness that certain visual stimuli are transmitted to the unconscious areas of the brain even with vision impairments. Nunaps facilitates new values and hopes to those suffering from brain problems.